Cingulate Inc
CINGW0.106USD
+0.010+10.10%
Horário de mercado （ET）Cotações atrasadas em 15 min
0.00Valor de mercado
--P/L TTM
Mais detalhes de Cingulate Inc Empresa
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Informações da empresa
Código da empresaCINGW
Nome da EmpresaCingulate Inc
Data de listagemOct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
Número de funcionários- -
Tipo de títulosCompany Warrant
Fim do ano fiscal- -
Endereço1901 W. 47Th Place
CidadeKANSAS CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal66205
Telefone19139422300
Sitehttps://www.cingulate.com/
Código da empresaCINGW
Data de listagemOct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Other
100.00%
Investidores
Investidores
Proporção
Other
100.00%
Tipos de investidores
Investidores
Proporção
Other
100.00%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
12
238.84K
0.00%
-824.25K
2025Q1
12
238.84K
0.00%
-824.25K
2024Q4
11
230.16K
0.00%
-848.35K
2024Q3
11
526.73K
0.00%
-559.74K
2024Q2
11
1.54M
0.00%
-29.99K
2024Q1
10
1.52M
0.00%
-577.42K
2023Q4
10
2.04M
0.00%
-3.83K
2023Q3
9
2.05M
0.00%
-52.84K
2023Q2
9
2.10M
0.00%
-175.37K
2023Q1
9
2.28M
0.00%
-7.12K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Hudson Bay Capital Management LP
210.80K
0%
--
--
Mar 31, 2025
Citadel Advisors LLC
12.58K
0%
-2.08K
-14.17%
Mar 31, 2025
GoalVest Advisory, LLC
3.00K
0%
--
--
Mar 31, 2025
Armistice Capital LLC
--
0%
-1.71K
-100.00%
Mar 31, 2025
Altium Capital Management LP
--
0%
-270.00K
-100.00%
Dec 31, 2024
Lynwood Capital Management Inc.
--
0%
-50.00K
-100.00%
Dec 31, 2023
Sabby Management, LLC
--
0%
-458.52K
-100.00%
Sep 30, 2024
Warberg Asset Management LLC
--
0%
-43.16K
-100.00%
Sep 30, 2024
Virtu Americas LLC
--
0%
-11.16K
-100.00%
Dec 31, 2024
BofA Global Research (US)
--
0%
-100.00
-100.00%
Sep 30, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
